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Effects of MDMA on body temperature in humans
Matthias E Liechti*
Division of Clinical Pharmacology and Toxicology; Department of Biomedicine and Department of Clinical Research; University Hospital and University of Basel; Switzerland
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Hyperthermia is a severe complication associated with the recreational use of 3,4-methylenedioxymethamphetamine
(MDMA, Ecstasy). In this review, the clinical laboratory studies that tested the effects of MDMA on body temperature are
summarized. The mechanisms that underlie the hyperthermic effects of MDMA in humans and treatment of severe
hyperthermia are presented. The data show that MDMA produces an acute and dose-dependent rise in core body
temperature in healthy subjects. The increase in body temperature is in the range of 0.2-0.8C and does not result in
hyperpyrexia (>40C) in a controlled laboratory setting. However, moderately hyperthermic body temperatures >38.0C
occur frequently at higher doses, even in the absence of physical activity and at room temperature. MDMA primarily
releases serotonin and norepinephrine. Mechanistic clinical studies indicate that the MDMA-induced elevations in body
temperature in humans partially depend on the MDMA-induced release of norepinephrine and involve enhanced
metabolic heat generation and cutaneous vasoconstriction, resulting in impaired heat dissipation. The mediating role of
serotonin is unclear. The management of sympathomimetic toxicity and associated hyperthermia mainly includes sedation
with benzodiazepines and intravenous fluid replacement. Severe hyperthermia should primarily be treated with additional
cooling and mechanical ventilation.
Introduction
Hyperpyrexia (body temperature>40C) is themost important
acute severe complication of the recreational use of 3,4-methylene-
dioxymethamphetamine (MDMA, Ecstasy). MDMA-induced
hyperpyrexia is relatively rare and not observed in placebo-con-
trolled studies in humans. However, moderate effects of MDMA
on body temperature have been documented in several placebo-
controlled laboratory studies in human subjects. This review sum-
marizes the clinical studies on MDMA-induced hyperthermic
effects and the potential pharmacological mechanisms that are
involved in humans. Many preclinical studies (for review, see1) but
relatively few clinical studies have evaluated the effects of MDMA
on body temperature. The present review focuses on the findings
from placebo-controlled studies that assessed MDMA in humans
and addresses treatment options for hyperpyrexia caused by recrea-
tional Ecstasy use. The thermal effects of Ecstasy in dance clubbers
have previously been described and summarized.2
Hyperthermia associated with Ecstasy use
The association between Ecstasy use and hyperpyrexia is well-
established,3-6 and reports were systematically compiled by Gru-
nau and colleagues.6 Hyperpyrexia is relatively rare, but if it
occurs, then it typically leads to intravascular coagulation,
rhabdomyolysis, and renal or other organ failure.2,4-10 In particu-
lar, body temperature >41C can result in fatalities.4,6 Moderate
forms of Ecstasy-induced hyperthermia (>38C) are frequently
observed. Increased body temperature (>37.1C) was found in
19% of patients,9 and hyperthermia (>38C) was found in 4%
of patients5 who presented in emergency departments with
Ecstasy-related medical problems.
Basic mechanisms involved in hyperthermia
Drug-induced hyperthermia resembles heat stroke. The basic
mechanisms include increased heat production and/or decreased
heat loss (Fig. 1). In heat stroke, heat dissipation is primarily
impaired by a hot environment, and heat generation is often
increased by exertion. In drug-induced hyperthermia, the drug
exertsdirectactionstoincreasemetabolicheatgenerationandreduce
heat dissipation as mostly studied in animals,7,11-13 whereas a hot
environment and exertion may act as additional permissive fac-
tors.2,14 Additionally, in the case of drug-induced hyperthermia,
central heat regulationmechanismsmay be disturbed.12Many psy-
chotropic substances, including both therapeutic medications and
recreational drugs, alter body and brain temperature15 and may
cause hyperthermia.12 Serotonin syndrome, which includes
increases in body temperature, may result when serotonergic drugs
are used at high doses or in combinations.16Neurolepticmalignant
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syndrome is an adverse hyperthermic reaction to antipsychotic
drugs.12MDMAreleases serotoninandthereforemay inducea sero-
tonin syndrome, including increased body temperature.17 Addi-
tionally, MDMA has been shown to induce alterations in
mitochondrial energymetabolism in animals, resulting in increased
heat generation instead of metabolic energy carrier (i.e., adenosine
triphosphate) production.11,18 Additionally, psychostimulants,
includingMDMA, constrict blood vessels via sympathetic stimula-
tion, including adrenergic receptor stimulation, thereby reducing
peripheralbloodflowandheatdissipationbyconvectionvia the skin
(Fig. 1).19 Furthermore, central thermoregulationmay be dysregu-
lated in the case of substances that act as direct or indirect serotonin
receptor agonists, such as MDMA.20 Dopaminergic mechanisms
have also been implicated inMDMA-inducedhyperthermia in pre-
clinical studies.21 Many permissive factors have been shown to
enhance the thermogenic effects ofMDMA, typically in preclinical
studies, and have been summarized with regard to humanMDMA
use.2Factorsthat increasetheriskofMDMA-inducedhyperthermia
in animals and possibly also in humans include multiple dosing
(booster) or high doses,2,22 high ambient temperature,7,23,24
reduced fluid intake,23 crowded conditions, physical activity,23 and
social interaction.24,25 Several of these risk factors are typically pres-
ent in dance clubs or party settings whereMDMAand other stimu-
lant drugs are consumed. Hyperthermia is also seen in human
MDMA exposure outside “rave” party settings in the absence of
physical activity.26 In placebo-controlled laboratory studies in
humans, these conditions are mostly not present for safety reasons.
In real-world studies of ecstasyusers at dance clubs, increases in tym-
panic body temperature ofC0.2 toC1.6Chave beenmeasured in
response toEcstasyuse(forasummary, seeParrott2).
Effects of MDMA on body temperature in experimental
clinical studies
Clinical laboratory studies that investigated the effects of
MDMA using a placebo-controlled study design are summarized
in Table 1. MDMA was administered orally in all these studies
but different doses were used. A series of small experimental stud-
ies (n < 20) assessed the thermogenic effects of MDMA in
healthy subjects.27-40 These studies typically used axillary, oral,
or tympanic temperature measurements. Body temperature was
not the primary outcome measure in these studies, with one
exception. Pooled analyses of the effects of MDMA have been
reported using aggregated data from smaller studies with 27 sub-
jects by da la Torre and colleagues,41 74 subjects by Liechti and
colleagues,34 and 80 subjects by Hysek and Liechti.32 In the stud-
ies by Liechti and colleagues,42-46 which were conducted in Zur-
ich, Switzerland, axillary body temperature was measured in a
total of 54 men and 20 women after MDMA doses of 1.35-
1.8 mg/kg.34 Peripheral body temperature was significantly
increased by 0.4C compared with placebo in male subjects,
whereas MDMA-induced increases in body temperature did not
reach statistical significance in the smaller group of female partic-
ipants.34 All axillary body temperatures remained below 38C.34
In our more recently published placebo-controlled studies per-
formed in Basel, Switzerland, core body temperature was mea-
sured using an ear thermometer and repeatedly after the
administration of MDMA at doses of 75 mg (n D 30) and
125 mg (n D 96) in a total of 126 healthy subjects.27-33 The
effects of the 75 mg dose of MDMA on body temperature were
reported by Schmid et al.47 The effects of the 125 mg dose of
MDMA were reported in a pooled analysis by Hysek and Liechti
(n D 80)32 and separately for 16 additional subjects.33,47
MDMA did not significantly alter body temperature at a dose of
75 mg compared with placebo in 30 subjects.47 The maximum
increase after MDMA was 0.35 § 0.06C above pretreatment
baseline compared with 0.25 § 0.06C after placebo.47 At a
higher dose of 125 mg, MDMA robustly and significantly
increased body temperature in several of our recent stud-
ies.27,28,30,31,33 The pooled data from 5 of these studies were pre-
sented in an analysis of the autonomic effects of MDMA in 80
healthy subjects32 and in a study of dose-response effects in the
online supplemental material that accompanied the reported by
Schmid et al.47 The increase in body temperature after 125 mg
of MDMA was typically 0.3-0.8C.32,47 As expected, a statisti-
cally significant MDMA dose-response effect on body tempera-
ture was observed.47 Maximal temperatures occurred 2-2.5 h
after MDMA administration and after subjective effects, heart
rate, or blood pressure had peaked, which was at 1.5 h.32 An
analysis of the data from all 126 subjects showed a peak maxi-
mum body temperature of 37.5 § 0.5C. After the 75 mg dose
of MDMA, tympanic temperatures remained below 38C in all
30 subjects. However, after the 125 mg dose in a total of 96 sub-
jects, tympanic temperatures were >38.0C in 21 subjects (22%)
and >38.5C in 3 subjects (3%), reaching a maximum of
39.1C in one subject (1%). Importantly, these body tempera-
tures were measured with subjects at rest and at a mean room
temperature of 22.7 § 0.6C. The time course of the increase in
tympanic body temperature after MDMA administration at a
dose of 125 mg in 96 subjects is shown in Figure 2. The figure
shows the pooled data from all our 6 published studies using the
125 mg dose of MDMA.27-31,33 Significant elevations in body
MDMA
serotonin
norepinephrine
dopamine
vasoconstricon
α1-receptor 
heat dissipaon
mitochondrial
uncoupling
β3-receptor 
heat generaon
serotonin syndrome
central temperature dysregulaon ?
hyperthermia
seng / environmental permissive factors
(dancing, crowded, hot environment)
set / individual risk
factors (genecs)
other drugs used
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?
Figure 1. Basic mechanism involved in 3,4-methylenedioxymethamphet-
amine (MDMA)-induced hyperthermia.
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temperature were observed between 90 min and 4 h after
MDMA administration.
Several other smaller studies have also evaluated the thermo-
genic effects of MDMA. Oral temperature slightly increased after
doses of 75 and 125 mg MDMA in 8 subjects, but no statistically
significant differences were observed compared with placebo.35
In the same study, amphetamine at an oral dose of 40 mg was
also without effects on oral temperature.35 A similar nonsignifi-
cant increase in oral temperature was found in another small
study that included 9 subjects and a dose of 100 mg.38 The same
group reported significant increases in oral temperature after
MDMA administration at doses of 75, 100, and 125 mg from a
pooled analysis of several studies that included doses of 50 mg (n
D 2), 75 mg (n D 10), 100 mg (n D 13), 125 mg (n D 8), and
150 mg (n D 2).41 Other small studies by different research
groups were also found. Harris and colleagues measured both
skin (i.e., index finger) and core (i.e., tympanic) temperature after
MDMA administration (0.5 and 1.5 mg/kg) in 8 subjects.37
Although skin temperature decreased 5.0 § 4C from pretreat-
ment levels after 1.5 mg/kg, it was not significantly lower than in
the placebo condition in this small study.37 The finding of
reduced finger skin temperature is consistent with reports of cold
extremities after MDMA administration and very likely reflects
vasoconstriction in the periphery and reduced heat dissipation.
Table 1. Placebo-controlled studies that investigated effects of MDMA on body temperature
Reference other drugs in study Sample size oral doses measurement effect
39 no n D 6 0.25-1.0 mg/kg oral no significant change
42 no n D 13 1.7 mg/kg axillary no significant change
35 amphetamine n D 8 75 and 125 mg oral no significant change
a41 no n D 27, pooled 50-150 mg oral increase after initial decrease
43 citalopram n D 16 1.5 mg/kg axillary increase
46 haloperidol n D 14 1.5 mg/kg axillary no significant change
44 ketanserin n D 14 1.5 mg/kg axillary increase
b34 no n D 74, pooled 1.35-1.8 mg/kg axillary increase
37 no n D 8 0.5 and 1.5 mg/kg finger and tympanic no significant change
36 mCPP, amphetamine n D 12 1 and 2 mg/kg oral increase
38 no n D 9 100 mg oral no significant change
50 no n D 10 2 mg/kg ccore body and skin increase (core), trend-increase (skin)
49 no n D 8 1.0 and 1.6 mg/kg tympanic no significant change
40 tetrahydrocannabinol n D 16 100 mg tympanic increase
27 reboxetine n D 16 125 mg tympanic increase
48 methamphetamine n D 11 100 mg oral no significant change
29 clonidine n D 16 125 mg tympanic no significant change
28 duloxetine n D 16 125 mg tympanic increase
30 carvedilol n D 16 125 mg tympanic increase
31 doxazosin n D 16 125 mg tympanic increase
d32 pooled analysis n D 80, pooled 125 mg tympanic increase
33 methylphenidate n D 16 125 mg tympanic increase
47 methylphenidate n D 30 75 mg tympanic no significant change
MDMA, 3,4-methylenedioxymethamphetamine; mCPP, metachlorophenylpiparazine.
apooled data including study 35 (n D 8) and an additional 19 subjects.
bpooled data including studies 42, 43, 46, and 44, and data from 16 subjects from study 45.
cingested radio-telemetry pill, chest, upper arm, thigh, and lower leg.
dpooled data including 27-31, and 33.
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Unfortunately, no other studies have measured finger tempera-
ture to confirm this finding in a larger sample. Kirkpatrick and
colleagues found that MDMA at an oral dose of 100 mg had no
effects on oral body temperature in 11 subjects.48 This study also
found no effects of methamphetamine (40 mg, orally) on body
temperature.48 Kolbrich and colleagues found nonsignificant ele-
vations in tympanic temperature in 8 healthy subjects with
MDMA doses of 1.0 and 1.6 mg/kg (46-150 mg).49 Tancer and
Johanson showed that MDMA at a dose of 2 mg/kg significantly
increased oral body temperature in 12 subjects.36 Significant
increases in tympanic temperature of 0.3C were also shown after
100 mg of MDMA in 16 subjects by Dumont and colleagues.40
A study by Freedman, Johanson, and Tancer provided a compre-
hensive evaluation of the effects of 2.0 mg/kg MDMA on core
and skin temperature at low (18C) and high (30C) ambient
temperatures.50 This also appears to be the only laboratory study
of the effects of MDMA in humans in which body temperature
was the primary outcome measure. In all of the other studies,
body temperature was a secondary measure. Core body tempera-
ture was measured in 10 subjects using an ingested radiotelemetry
pill.50 Skin temperature was measured at the chest, upper arm,
thigh, and lower leg, and a weighted average was calculated.
Absolute core temperatures were higher after MDMA in the
warm environment compared with the cold environment. How-
ever, core temperature was also higher in the warm environment
compared with the cold environment after placebo. Thus,
MDMA similarly increased core temperature at the low and high
ambient temperatures compared with placebo.50 These increases
were related to increases in metabolic rate, measured by indirect
calorimetry, in the same study. Skin temperature was markedly
increased in the hot and decreased in the cold environment, and
MDMA produced a near-significant increase in skin temperature
under both temperature conditions and compared with
placebo.50
Altogether, considering the pooled data analyses from our lab-
oratory and those of the Freedman study, MDMA is well docu-
mented to produce an acute and dose-dependent elevation in
core body temperature in healthy subjects. The increase in body
temperature is also evidently rather small, in the range of 0.2-
0.8C, and does not result in hyperpyrexia (>40C) in a con-
trolled laboratory setting. Importantly, no laboratory study
observed MDMA-induced hyperpyrexia in a controlled setting.
However, moderately hyperthermic body temperatures >38.0C
were documented in a substantial number of our subjects (23%
after a 125 mg dose in our sample), demonstrating that MDMA
induces moderate hyperthermia even in the absence of any per-
missive factors and at room temperature (23C).
Neurochemistry of the thermogenic properties of MDMA
in humans
Several mechanistic studies assessed the effects of pharmaco-
logical pretreatments on the response to MDMA in healthy sub-
jects to evaluate the mediating role of different neurotransmitters
and receptors. These human studies also provide important infor-
mation on the mechanisms involved in MDMA-induced
increases in body temperature and likely also in the more severe
hyperpyrexia associated with uncontrolled use. MDMA mainly
releases serotonin and norepinephrine and to a lesser extent dopa-
mine through the corresponding presynaptic monoamine trans-
porters.28,51 MDMA also interacts directly with monoamine
receptors52,53 but only at relatively high concentrations, likely
making these effects less relevant in humans. Serotonin trans-
porter inhibitors block the interaction between MDMA with the
transporter to release serotonin.28 Transporter inhibitors, there-
fore, can be used as pharmacological tools to investigate the role
of serotonin release in the mechanism of action of MDMA. Sero-
tonin transporter inhibitors reduced the psychotropic and most
physiological effects of MDMA in healthy humans,43,54-56 sug-
gesting a mediating role for serotonin in most effects of MDMA
in humans. Regarding the thermogenic effects of MDMA, sero-
tonin transporter inhibition reduced MDMA-induced increases
in oral55 but not axillary body temperature.43 The combined
serotonin and norepinephrine transporter inhibitor duloxetine
also tended to attenuate the MDMA-induced increase in body
temperature in humans, but the effect was not significant.28
These findings are inconclusive but are consistent with the view
that both serotonin and norepinephrine are involved in the
effects of MDMA on body temperature. Interestingly, in ani-
mals, serotonin transporter inhibition reduced MDMA-induced
hyperthermia in mice57 but not rats.21 Serotonin release is the
major mediator of most of the clinical effects of MDMA, but its
precise role in the thermogenic response in humans remains to
be determined. The serotonin 5-HT2A receptor antagonist ketan-
serin reduced the MDMA-induced elevation in body tempera-
ture in humans,44 consistent with studies in rats.58 However, in
humans, ketanserin alone also reduced body temperature com-
pared with placebo, and the effects with MDMA were therefore
Figure 2. Effects of 3,4-methylenedioxymethamphetamine (MDMA,
125 mg orally) and placebo on core body (tympanic) temperature in
healthy subjects. Absolute raw data values from all subjects who partici-
pated in our 6 placebo-controlled experimental studies using a dose of
MDMA of 125 mg MDMA27-31,33 were pooled and are presented here as
mean§ SEM of absolute tympanic temperature values in 96 healthy sub-
jects (48 male and 48 female). MDMA significantly increased body tem-
perature compared with placebo (repeated-measures analysis of
variance: time £ drug interaction: F10,940 D 19.72, P < 0.001). *** for P <
0.001 indicate significant differences compared with placebo for individ-
ual time points based on Tukey post hoc test. MDMA or placebo was
administered at t D 0. MDMA was administered in a quiet hospital set-
ting and the subjects were not physically active.
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mostly additive.44 Additionally, ketanserin has a1-adrenergic
receptor-blocking properties59 and may reduce peripheral vascu-
lar resistance and body temperature. The serotonin 5-HT1A
receptor antagonist pindolol did not alter the MDMA-induced
increase in body temperature in humans,60 also consistent with
preclinical data.58 Potential dopaminergic mediation of the
effects of MDMA on body temperature has not been well-studied
in humans. Preclinical data suggest a role for the dopamine D1
receptor in the mediation of hyperthermia associated with
MDMA.21 Because no selective D1 antagonists are available for
human use, the role of the D1 receptor has not been studied in
humans. The interaction between MDMA and the dopamine D2
receptor antagonist haloperidol was examined in healthy subjects,
but MDMA did not produce significant elevations in body tem-
perature in that study to provide meaningful results.46 Studying
the role of the dopamine transporter in MDMA-induced hyper-
thermia using pharmacological tools was also difficult because
dopamine transporter inhibitors may not effectively block
MDMA-induced dopamine release21 or may have effects on their
own.61 In fact, the dopamine uptake inhibitor methylphenidate
increased body temperature in healthy subjects when given alone
but failed to alter the thermogenic response to MDMA when
administered prior to MDMA.33,47 In contrast, MDMA did not
produce an increase in body temperature in humans after pre-
treatment with the selective norepinephrine transporter blocker
reboxetine.27 Additionally, reboxetine blocked MDMA-induced
increases in norepinephrine plasma levels and elevations in heart
rate and blood pressure,27 supporting the view that norepineph-
rine rather than serotonin is critical in the mediation of not only
the cardiovascular but also hyperthermic response to MDMA.
Further human studies examined the contributing role of differ-
ent adrenergic receptors. b1-adrenergic receptors did not appear
to be involved because the b1-receptor blocker pindolol did not
alter the temperature response to MDMA in humans.60 Admin-
istration of the non-selective b-receptor antagonists propranolol
or nadolol also had no effect on the thermogenic response to
MDMA in rats.62 The a2-adrenergic receptor agonist and sympa-
tholytic drug clonidine, which is expected to reduce central
adrenergic output, lowered body temperature in humans when
given alone but not the MDMA-induced elevations in body tem-
perature.29 In contrast, the a1-adrenergic receptor antagonist
doxazosin reduced the increase in body temperature induced by
MDMA in humans.31 This is again consistent with the view that
MDMA-induced increases in norepinephrine mediate the ther-
mogenic effects of MDMA and that increases in body tempera-
ture are linked to cutaneous vasoconstriction that results in
impaired heat dissipation, and doxazosin prevents a1-adrenergic
receptor-mediated vasoconstriction. Peripheral vasoconstriction
and improper heat dissipation have also been identified as critical
mechanisms that underlie MDMA-induced core (brain) hyper-
thermia in rats treated with MDMA under conditions that simu-
late drug use in humans.24 Additionally, the combined a1- and
b1-3-adrenergic receptor antagonist carvedilol effectively pre-
vented temperature elevations in healthy subjects,30,63 consistent
with preclinical data.62 This latter finding is particularly interest-
ing because carvedilol is expected to block both MDMA-induced
heat generation by mitochondrial uncoupling18,64, by blocking
b3-adrenergic receptor- and a1-adrenergic receptor-mediated
vasoconstriction. In fact, carvedilol more effectively reduced the
hyperthermic response to MDMA compared with a1 receptor
blockade in both animals62 and humans.30,31 Similarly, both the
a1-antagonist prazosin and the b3-antagonists cyanopindolol
only partly attenuated body temperature increases in skeletal
muscle (cyanopindolol) or core (prazosin) after MDMA and the
combination of the 2 completely blocked MDMA-induced
hyperthermia (muscle and core).65 Additionally, carvedilol
reduced MDMA-induced increases in both heart rate and blood
pressure in healthy human subjects.30 Thus, carvedilol reduced
several signs of sympathetic activation by MDMA including the
cardiostimulant and the termogenic effects.
Dumont and colleagues studied the interactive effects of
MDMA and tetrahydrocannabinol in healthy subjects. Tetrahy-
drocannabinol delayed the MDMA-induced increase in tempera-
ture, and the duration of the temperature elevation was
prolonged, although the mean temperature increase was compa-
rable to administration of MDMA alone.40 The results indicate
that tetrahydrocannabinol is unlikely to protect against MDMA-
induced hyperthermia, although cannabinoids decrease body
temperature in rats66 and in contrast to previous hypotheses.67
Several experimental human studies also tested the effects of
other psychostimulants with a slightly different pharmacology
than MDMA on body temperature. Various psychostimulants,
including MDMA, enhance noradrenergic neurotransmission,
but their relative dopaminergic vs. serotonergic activity varies.
For example, Tancer and Johanson assessed the effects of
MDMA, D-amphetamine (mostly a dopamine and norepineph-
rine releaser), and metachlorophenylpiperazine (a serotonin
inhibitor and releaser) on oral temperature in the same study.36
Both amphetamine and metachlorophenylpiperazine increased
body temperature similarly to MDMA.36 The data suggest that
psychotropics with either serotonergic (metachlorophenylpipera-
zine) or dopaminergic (amphetamine) properties increase body
temperature. Similar to amphetamine, methylphenidate (a selec-
tive dopamine and norepinephrine transporter inhibitor with no
serotonergic properties) also acutely increased body temperature
in humans when given at a dose of 40 mg47 or 60 mg.33 Cocaine
enhanced the progressive increase in core body temperature dur-
ing passive heating.68 The elevation in body temperature was
attributable to impaired heat dissipation, including reduced
sweating and cutaneous vasodilation.68 Similar to MDMA,
cocaine has serotonergic and noradrenergic properties.52 Impor-
tantly, all of these recreational drugs, whether serotonergic
(MDMA or metachlorophenylpiperazine) or dopaminergic
(amphetamine or methylphenidate) or both (cocaine), also
enhance norepinephrine transmission. Therefore, norepinephrine
likely contributes to the thermogenic effects of these substances,
consistent with the reducing effects of carvedilol on the tempera-
ture response to MDMA.
A series of novel psychoactive substances with structural similar-
ity to MDMA have been implicated in hyperpyrexia. In particular,
para-methoxyamphetamine and para-methoxymethamphetamine,
which are occasionally sold as Ecstasy,69 have been associated with
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an especially high risk of hyperthermia.69-72 Para-methoxyamphet-
amine and para-methoxymethamphetamine predominantly act on
the serotonin system,73 consistent with the role of serotonin in
hyperthermia. Four-Methylthioamphetamine is another seroto-
nergic compound73 that has been linked to hyperthermia.74 Other
novel substances, such as 3,4-methylendioxypyrovalerene, which
potently inhibits dopamine and norepinephrine uptake52 and
induces marked and prolonged agitation, has also been reported to
induce hyperthermia.75 Notably, hyperthermia has also been
described with the dopamine and norepinephrine transporter
inhibitor methylphenidate.76
Altogether, the mechanistic studies in humans provide sup-
port for the conclusion that MDMA mainly increases body tem-
perature via the release of norepinephrine, which then increases
metabolic heat generation and impairs heat dissipation via vaso-
constriction. Additionally, the release of serotonin may also con-
tribute to the thermogenic effects of MDMA in humans.
Management of Ecstasy-induced hyperthermia in patients
The various treatments for hyperpyrexia induced by MDMA
or other psychostimulants have not been systematically evaluated
in the emergency room setting. Hyperthermic complications are
relatively rare, and clinical trials are unlikely to be conducted.
However, as described above, several placebo-controlled mecha-
nistic experimental studies have been conducted with healthy
subjects, which can inform us on the pharmacological mecha-
nism of MDMA-induced hyperthermia in humans and potential
effects of pharmacological treatments. As a limitation, the experi-
mental studies used doses of pure MDMA in the range of 50-
150 mg while recreational users of ecstasy pills may ingest
MDMA at lager doses or repeated doses. For example, in an nat-
uralistic observational study among 49 partying people, 34 used
doses of MDMA of 0-150 mg while 15 took cumulative doses of
150-280 mg.77 An analysis of ecstasy pills from 5,786 recrea-
tional users found an average MDMA content in the ecstasy pills
of 82.5 § 35.2 mg.69 Approximately 20% of users presenting to
emergency departments with medical problems report having
ingested 2 or more pills.5,9 Additionally, MDMA is often used in
combination with other substances5,9 many of which may also
affect body temperature.
Paramedics and emergency department personnel must recog-
nize hyperthermia in subjects with acute substance-induced dis-
orders. It is not uncommon that agitated subjects die of
hyperpyrexia because body temperature was not measured, and
elevations in body temperature went unrecognized. Agitated sub-
jects should not be restrained. Sedation with benzodiazepines
and intravenous fluid replacement are the most important acute
supportive care measures in patients with substance-induced
sympathomimetic toxidromes and/or agitation.3,5,78 The man-
agement of hyperpyrexia includes cooling (fanning, water, ice
packs, ice bath, cooling blankets) and mechanical ventilation.10
Dantrolene, which acts at skeletal muscles to inhibit the release
of calcium, has also been used.6,10,79 However, dantrolene does
not inhibit the thermogenic effects of MDMA,80 and the drug
does not modulate the mechanism of MDMA-induced
hyperthermia discussed above. Nevertheless, case reports support
its benefits in cases of extreme hyperpyrexia (>42C).6
Antipsychotics, such as haloperidol, should not be used as a
routine treatment of drug-induced agitation or only with great
care and after treatment with benzodiazepines. Antipsychotics are
associated with hyperthermia in the context of neuroleptic malig-
nant syndrome and some (e.g., phenothiazines) also act as anti-
cholinergics and potentially reduce sweating and thus heat
dissipation by evaporation. Additionally, haloperidol has been
shown to enhance acute anxiety and the negative mood effects of
MDMA46 and psilocybin.81 Thus, the use of this antipsychotic
medication may actually enhance adverse drug effects, at least in
certain situations. The atypical antipychotic clozapine has been
shown to reverse hyperthermia and cutaneous vasoconstriction
induced by MDMA in rats or rabbits82 but human data to sup-
port its clinical use are lacking. Hyperthermia is often associated
with other signs of sympathomimetic stimulation, including agi-
tation, tachycardia, and hypertension. Benzodiazepines are also
beneficial in the treatment of these symptoms. However, addi-
tional hypertensive treatment with vasodilators, such as nitrates,
may be needed. Adrenergic receptor antagonists can be useful.
However, b blockade without a blockade should be avoided in
drug-induced sympathomimetic toxicity because of the unop-
posed a-adrenergic receptor stimulation that enhances vasocon-
striction83 and results in further increases in blood pressure60,84
and possibly body temperature. In contrast, a blockade reduced
the blood pressure response to MDMA and elevations in body
temperature,31 and combined a/b blockade reduced MDMA-
induced increases in blood pressure, heart rate, and body temper-
ature30,63 and blood pressure response to cocaine.85-87 Accord-
ingly, a blockers (e.g., phentolamine) or a/b blockers (e.g.,
carvedilol) could be useful in situations of extreme sympathomi-
metic stimulation, although real-world clinical data are mostly
lacking. Phentolamine was successfully used to treat a hyperten-
sive emergency caused by amphetamine overdose.88
Besides from hyperthermia, brain edema is another severe
complication of MDMA use. MDMA induces a syndrome of
inappropriate secretion of antidiuretic hormone89-91 which may
lead to symptomatic hyponatremia including brain edema in par-
ticular in women.92-94 Thus, excessive water consumption but
also fluid treatment can be potentially dangerous in the preven-
tion or the treatment of MDMA-induced hyperthermia. Addi-
tionally, animal studies indicate that the blood-brain barrier is
disrupted during MDMA-induced hyperthermia also leading to
brain edema.95
Conclusion
MDMA increases body temperature in humans. However,
hyperpyrexia (>40C) is not seen in controlled laboratory set-
tings. The MDMA-induced elevations in body temperature in
humans appear to depend on the MDMA-induced release of nor-
epinephrine and involve cutaneous vasoconstriction and likely
also enhanced metabolic heat generation. The role of serotonin
needs further clarification. The management of overdose cases
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includes sedation treatment with benzodiazepines, intravenous
fluid replacement, and additional cooling and mechanical venti-
lation in severe cases.
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